RxDoctor Payments Data

Thomas Chapman, DO

Internal Medicine · Kansas City, MONPI 1932167897

Payments from drug & device makers

$4,226in general payments, 2019–2025

Across 280 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$301
  • Lilly USA, LLC$297
  • Novo Nordisk$239
  • GSK$227
  • Amarin Pharma, Inc.$214
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,226 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$182,535
Medicare patients
360
Services billed
9,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin156$204,202
MounjaroTirzepatide112$192,591
EliquisApixaban150$145,631
OzempicSemaglutide48$62,326
FarxigaDapagliflozin Propanediol53$61,881
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$43,418
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$39,932
UbrelvyUbrogepant18$25,869
XareltoRivaroxaban27$25,799
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$23,397
CreonLipase/Protease/Amylase12$20,219
VraylarCariprazine Hcl12$20,116
MyrbetriqMirabegron22$18,716
ArexvyRsvpref3 Antigen/As01e/Pf53$14,465
Xtampza ErOxycodone Myristate25$12,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$123$212,567173 claims
Lilly USA, LLCMounjaro$297$192,591112 claims
PfizerEliquis, Abrysvo$95$155,824184 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$301$93,224101 claims
AbbVieUbrelvy, Creon, Vraylar, Synthroid$1,016$69,94483 claims
Novo NordiskOzempic$239$62,32648 claims
GSKTrelegy Ellipta, Arexvy$227$57,88289 claims
Johnson & JohnsonXarelto$14$25,79927 claims
Astellas Pharma US IncMyrbetriq$41$18,71622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →